Catalyst Event
Pfizer Inc (PFE) · Other
From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)
6/8/2026, 12:00:00 AM
Pfizer announced detailed positive results from its Phase 2b trial for berobenatide, an investigational monthly GLP-1 receptor agonist for obesity, demonstrating competitive weight loss and favorable tolerability on June 8, 2026, expected. Estimated medium impact as obesity market is high-growth.
Korean Translation
화이자, 2026년 6월 8일 비만 치료를 위한 월 1회 투여 GLP-1 수용체 작용제 후보물질 베로베나타이드(berobenatide)의 2b상 임상시험 결과 발표가 예상됨. 비만 치료제 시장 성장성에 따른 중간 수준의 영향 예상됨.
Related Recent Events
Kinder Morgan Inc. (KMI) · Other
James Holland, Chief Operating Officer, is set to retire, effective September 4, 2026. Ken Grubb, currently VP and Chief Project Officer, will succeed him as COO. The transition was announced on April 22, 2026. Impact is estimated at 1% due to the planned nature of the succession scheduled.
9/4/2026, 12:00:00 AM
HEICO Corp (HEI) · Earnings Release
Q3 2026 earnings release on 2026-08-24 scheduled.
8/24/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Q2 FY2027 earnings release scheduled; medium impact from financial updates expected.
8/20/2026, 12:00:00 AM
Target Corp (TGT) · Earnings Release
Q2 2026 earnings release on August 19, 2026, with analysts forecasting an EPS of approximately $2.21-$2.25; low impact estimated as the market typically prices in consensus expectations prior to the release expected.
8/19/2026, 12:00:00 AM
CoreWeave Inc (CRWV) · Earnings Release
Q2 2026 earnings release for August 18, 2026, is of high importance as such releases often cause >10% price impact; event scheduled.
8/18/2026, 12:00:00 AM
Home Depot Inc. (The) (HD) · Earnings Release
Q2 2026 earnings release and conference call on August 18, 2026. Estimated price impact ~5% as earnings releases typically drive significant volatility; scheduled.
8/18/2026, 12:00:00 AM